Restricted accessLetterFirst published online 2024-07
Interleukin-17 Monoclonal Antibody Successfully Treated Psoriasiform Drug Eruption Induced by Immune Checkpoint Inhibitors: A Case Report and Review of Literature
National Health Commission Of The People's Republic of China. National guidelines for diagnosis and treatment of esophageal carcinoma 2022 in China (English version). Chin J Cancer Res. 2022; 34(4):309–334.
2.
ChenCH, YuHS, YuS. Cutaneous adverse events associated with immune checkpoint inhibitors: a review article. Curr Oncol. 2022; 29(4):2871–2886.
3.
JohnsonD, PatelAB, UemuraMI, et al.IL17A blockade successfully treated psoriasiform dermatologic toxicity from immunotherapy. Cancer Immunol Res. 2019; 7(6):860–865.
4.
YuS, WuX, ShiZ, et al.Diet-induced obesity exacerbates imiquimod-mediated psoriasiform Dermatitis in anti-PD-1 antibody-treated mice: implications for patients being treated with checkpoint inhibitors for cancer. J Dermatol Sci. 2020; 97(3):194–200.
5.
LiS, NaR, LiX, et al.Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer. Biochim Biophys Acta Rev Cancer. 2022; 1877(4):188758.
